Cite

    Neumann, T. et al. (2018). No indication of increased infection rates using low‐dose alemtuzumab instead of anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis before allogeneic stem cell transplantation. Transplant infectious disease. 20 (1), p. n/a. [Online].